Bevacizumab biosimilar - mAbixience

Drug Profile

Bevacizumab biosimilar - mAbixience

Alternative Names: BEVZ92

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator mAbxience
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Switzerland (IV, Infusion)
  • 15 Mar 2016 Biomarkers information updated
  • 03 Sep 2015 National Cancer Institute plans a phase II trial for Brain metastases in USA (NCT02531659)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top